OBP Ondine Biomed

 
TIDMOBP 
 
Ondine Files PMA Submission for Periowave(TM) Photodisinfection System 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
January 7, 2010 
 
Ondine Files PMA Submission for Periowave(TM) Photodisinfection System 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 7, 2010) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP), a 
medical technology company developing photodisinfection-based products, announces that it has filed a premarket 
approval (PMA) submission with the United States Food and Drug Administration (FDA) seeking approval for 
marketing of the Periowave(TM) Photodisinfection System in the United States for the treatment of chronic 
periodontitis in adults as an adjunct to standard methods of care. 
 
"The PMA submission represents a major milestone for Ondine and our business partner, Periowave Dental 
Technologies, Inc.," said Carolyn Cross, Chairman & CEO of Ondine. "The submission incorporates the results of 
many years of preclinical and clinical development. We are proud of the dedicated team of our employees, 
clinicians and consultants who participated in the technical development, clinical studies and the FDA 
submission for Periowave(TM). We believe that Periowave(TM) has the potential to provide clinicians with an 
important new approach to the treatment of periodontitis, a widespread and chronic gum disease." 
 
About Periowave(TM) 
 
Periowave(TM) is a non-antibiotic photodisinfection system developed by Ondine that utilizes a low-intensity 
diode laser and a wavelength-specific, light-activated photosensitive compound which, when used in conjunction 
with standard methods of dental care, reduces the symptoms of chronic periodontitis. The photosensitizing 
solution is topically applied to the treatment site and preferentially stains pathogenic microbes present at 
the site. Once activated by the Periowave(TM) laser, the sensitizer rapidly destroys the pathogens as well as 
pathogen-associated virulence factors, significantly improving clinical outcomes. The photodisinfection process 
is designed to avoid the development of antibiotic resistance. The Photodynamic Disinfection technologies were 
developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College 
London. Periowave(TM) is currently approved in Canada and the European Union for the treatment of a number of 
gum diseases, including periodontitis, peri-implantitis, and peri-mucositis. In June of 2009, Ondine sold its 
dental healthcare business to Periowave Dental Technologies, Inc. (PDT). Under the terms of the sale, the 
Company is entitled to receive royalties and milestone payments based on sales of the Periowave(TM) 
Photodisinfection System by PDT, Ondine continues to be the manufacturer of the product and is responsible for 
obtaining regulatory clearance for marketing of the product in the United States. 
 
For more information about the FDA & the submission review process, please visit the FDA website at: 
www.fda.gov. 
 
About Ondine Biopharma Corporation 
 
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and 
viral infections. The Company is focused on developing leading edge products utilizing its patented light- 
activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the 
formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, 
with a research and development laboratory in Bothell, Washington, USA. For additional information, please 
visit the Company's website at: www.ondinebiopharma.com. 
 
Forward-Looking Statements: 
 
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and 
other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. 
Factors that could cause actual results to differ materially from those projected in the Company's forward- 
looking statements include the following: market acceptance of our technologies and products; our ability to 
obtain financing; our financial and technical resources relative to those of our competitors; our ability to 
keep up with rapid technological change; government regulation of our technologies; our ability to enforce our 
intellectual property rights and protect our proprietary technologies; the ability to obtain and develop 
partnership opportunities; the timing of commercial product launches; the ability to achieve key technical 
milestones in key products and other risk factors identified from time to time in the Company's public filings. 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
(604) 669-0555 
ccross@ondinebiopharma.com 
www.ondinebiopharma.com 
 
OR 
 
Canaccord Adams Ltd. 
Ryan Gaffney 
Nominated Adviser 
+4420 7050 6500 
 
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this 
release. 
 
 
 
 
Ondine Biopharma Corporation 
 

Ondine Biomed (LSE:OBP)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Ondine Biomed (LSE:OBP)
Gráfica de Acción Histórica
De May 2023 a May 2024